Masimo Research and Development Expenses 2010-2024 | MASI

Masimo research and development expenses for the twelve months ending June 30, 2024 were $0.181B, a 8.53% decline year-over-year.

  • Masimo annual research and development expenses for 2023 were $0.175B, a 8.46% decline from 2022.
  • Masimo annual research and development expenses for 2022 were $0.191B, a 39.5% increase from 2021.
  • Masimo annual research and development expenses for 2021 were $0.137B, a 15.59% increase from 2020.

Masimo Research and Development Expenses 2010-2024 | MASI

  • Masimo annual research and development expenses for 2023 were $0.175B, a 8.46% decline from 2022.
  • Masimo annual research and development expenses for 2022 were $0.191B, a 39.5% increase from 2021.
  • Masimo annual research and development expenses for 2021 were $0.137B, a 15.59% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$212.6B
Intuitive Surgical (ISRG)$186.7B
Alcon (ALC)$45.7B
IQVIA Holdings (IQV)$39.5B
Edwards Lifesciences (EW)$38.8B
IDEXX Laboratories (IDXX)$35.5B
DexCom (DXCM)$26.9B
Waters (WAT)$22.9B
SONOVA HOLDING (SONVY)$22B
STERIS (STE)$21.3B
Hologic (HOLX)$18.4B
Fresenius Medical Care AG KGaA (FMS)$12.5B
Sysmex ADR (SSMXY)$12.4B
Globus Medical (GMED)$11.1B
Teleflex (TFX)$9.2B
Penumbra (PEN)$8.9B
Glaukos (GKOS)$7.7B
PROCEPT BioRobotics (PRCT)$5B
Integer Holdings (ITGR)$4.5B
Inari Medical (NARI)$3B
TransMedics (TMDX)$2.9B
Veracyte (VCYT)$2.9B
LivaNova (LIVN)$2.8B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2.2B
Integra LifeSciences Holdings (IART)$2B
RxSight (RXST)$1.9B
Alphatec Holdings (ATEC)$1.3B
Artivion (AORT)$1.2B